Opthea Ltd (ASX: OPT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Opthea Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $391.06 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 662.81 million
Earnings per share -0.301
Dividend per share N/A
Year To Date Return 7.89%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Opthea Ltd (ASX: OPT)
    Latest News

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today

    These ASX shares are having a tough time on Thursday. But why?

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Opthea, Pantoro, Premier Investments, and Wildcat shares are falling

    These ASX shares are having a tough time on Tuesday. But why?

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why APA Group, Cettire, Deep Yellow, and Opthea shares are falling today

    These ASX shares are having a difficult session. Here's what's happening.

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    Why Arcadium Lithium, Boart Longyear, Opthea, and Orecorp shares are rising today

    These ASX shares are having a positive start to the week. But why?

    Read more »

    A scientist examining test results.
    Healthcare Shares

    Why did the Opthea share price dive 9% on Monday?

    The biopharmaceutical company has announced new share issue arrangements.

    Read more »

    Close up of a sad young woman reading about declining share price on her phone.
    Share Fallers

    Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking

    These ASX shares are having a bad start to the week...

    Read more »

    share price dropping
    Share Fallers

    Why Afterpay, Atomo, Opthea, & Sealink shares are falling today

    These ASX shares are in the red on Tuesday...

    Read more »

    Young man with laptop watching stocks and trends while thinking
    Small Cap Shares

    4 small cap ASX shares to watch

    Check out these small cap shares...

    Read more »

    A shocked man sits at his desk looking at his laptop while talking on his mobile phone with declining arrows in the background representing falling ASX 200 shares today
    Share Fallers

    Why Nanosonics, Oil Search, Opthea, & Piedmont Lithium are tumbling

    These ASX shares are in the red on Wednesday...

    Read more »

    green arrow representing a rise in the share price
    Share Market News

    Why Bigtincan, Oil Search, Opthea, & Xref shares are racing higher

    It has been a great day for these shares...

    Read more »

    A woman sits inside a cubicle undergoing an eyetest
    Healthcare Shares

    Here's why the Opthea (ASX:OPT) share price is soaring 8%

    This biopharmaceutical company is developing therapies to treat progressive retinal diseases.

    Read more »

    An older woman high fives an older man with big smiles after seeing good news on their laptop regarding their ASX tech shares
    Share Gainers

    Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher

    The market may be trading lower but these ASX share aren't...

    Read more »

    Frequently Asked Questions

    No, Opthea does not pay shareholder dividends at this time.

    Opthea Limited listed on the ASX on 18 April 1991. 

    OPT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Opthea Ltd

    Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage. 

    OPT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 May 2024 $0.59 $-0.03 -4.88% 754,519 $0.63 $0.64 $0.59
    27 May 2024 $0.62 $-0.03 -4.69% 361,079 $0.64 $0.64 $0.61
    24 May 2024 $0.64 $0.00 0.00% 114,434 $0.63 $0.64 $0.62
    23 May 2024 $0.64 $0.00 0.00% 144,416 $0.64 $0.64 $0.62
    22 May 2024 $0.64 $0.00 0.00% 1,957,400 $0.64 $0.64 $0.63
    21 May 2024 $0.64 $-0.01 -1.55% 245,900 $0.61 $0.64 $0.61
    20 May 2024 $0.65 $0.02 3.17% 360,075 $0.63 $0.65 $0.61
    17 May 2024 $0.63 $-0.04 -5.97% 558,962 $0.67 $0.67 $0.63
    16 May 2024 $0.67 $0.00 0.00% 271,173 $0.67 $0.67 $0.66
    15 May 2024 $0.67 $0.02 3.08% 417,502 $0.66 $0.67 $0.65
    14 May 2024 $0.65 $-0.03 -4.44% 942,557 $0.69 $0.69 $0.65
    13 May 2024 $0.68 $-0.01 -1.47% 457,670 $0.69 $0.70 $0.67
    10 May 2024 $0.68 $0.05 7.87% 1,250,268 $0.67 $0.72 $0.65
    09 May 2024 $0.64 $0.01 1.60% 267,391 $0.63 $0.65 $0.62
    08 May 2024 $0.63 $-0.03 -4.62% 101,447 $0.65 $0.65 $0.63
    07 May 2024 $0.65 $0.00 0.00% 671,689 $0.66 $0.69 $0.65
    06 May 2024 $0.65 $0.04 6.50% 1,066,922 $0.62 $0.68 $0.62
    03 May 2024 $0.62 $0.01 1.64% 8,524,328 $0.61 $0.63 $0.61
    02 May 2024 $0.61 $-0.01 -1.61% 468,107 $0.63 $0.63 $0.61
    01 May 2024 $0.62 $0.00 0.00% 363,003 $0.63 $0.63 $0.61
    30 Apr 2024 $0.62 $-0.02 -3.13% 1,078,693 $0.63 $0.65 $0.62

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Mar 2024 Megan Baldwin Sell 987,723 $543,247
    As advised by the company. Sale of 987,723 ordinary shares to cover
    personal tax obligations
    01 Mar 2024 Megan Baldwin Sell 3,012,277 $1,656,752
    As advised by the company. Sale of 3,012,277 ordinary shares to cover
    personal tax obligations
    21 Dec 2023 Jeremy Levin Issued 3,000,000 $1,410,000
    Issue of options.
    21 Dec 2023 Anshul Thakral Issued 1,000,000 $470,000
    Issue of options.
    21 Dec 2023 Lawrence Gozlan Issued 500,000 $235,000
    Issue of options. As per announcement on 21-12-2023
    21 Dec 2023 Megan Baldwin Issued 3,000,000 $1,410,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Lawrence Bernard Gozlan Non-Executive Director Jul 2020
    Mr Gozlan, a biotechnology investor and advisor, is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr Gozlan is also the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively on life sciences. Scientia was founded to provide high level expertise and to manage investments for high-net-worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. 20 Opthea Limited Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking and gained senior corporate finance experience advising life science companies at Deloitte.
    Dr Jeremy Levin Non-Executive ChairmanNon-Executive Director Oct 2020
    Dr Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. Dr. Levin held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the executive committee at Bristol Myers Squibb Company.
    Dr Julia Haller Non-Executive Director Jun 2021
    Dr Haller has served as Ophthalmologist in Chief and William Tasman. ME Endowed Chair at Wills Eye Hospital in Philadelphia. She is Professor and Chair of the Department of Ophthalmology at the Sidney Kimmel Medical College at Thomas Jefferson University as well as a Director of Bristol Myers Squibb and Outlook Therapeutics. She is a member of the National Academy of Medicine, the Chair of the College of Physicians of Philadelphia, Chair of the Heed Ophthalmic Society, past president of the Women in Medicine Legacy Foundation, and serves on several prestigious boards including the board of the John Hopkins Medical and Surgical Association, the Association of University Professors of Ophthalmology, and the Society of Heed Fellows.
    Dr Susan Orr Non-Executive Director Apr 2022
    Dr Orr is an experienced medical and business leader with specialization in identifying, developing and commercializing ophthalmic therapeutic product candidates. Dr Orr currently serves as the Chief Medical Officer at Claris Biotherapeutics and is a member of the Retina Global Board of Directors. Before Claris, Dr Orr was the Chief Executive Officer at Notal Vision subsequent to joining the company as Chief Medical Officer. Dr Orr has spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing. Dr Orr participated in multiple acquisitions including Durezol and Beovu and has been a Managing Partner at Fovenedeye Consulting.
    Mr Quinton Oswald Non-Executive Director Apr 2022
    Mr Oswald brings over 25 years of international general management experience, including onsite assignments in the US, Europe and South Africa. Most recently, he was the CEO of Notal Vision, a commercial stage ophthalmic home monitoring services provider with a focus on both wet and dry AMD. Prior to Notal Vision, he served as the CEO of Neurotech and, prior to that, as the CEO of SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra) for the treatment of dry eye disease, and its subsequent sale to Shire, PLC. Previously, he was Vice President and Business Unit Head for Genentech's tissue growth and repair business. During his tenure at Genentech, Mr Oswald oversaw the highly successful commercial launch of Lucentis (ranibizumab) for the treatment of wet AMD. Before Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne.
    Mr Anshul Thakral Non-Executive Director Jun 2023
    Mr Thakral is Chief Executive Officer and Board Member of Launch Therapeutics, a clinical development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Mr Thakral has worked for over 20 years in the pharmaceutical and biotechnology industry and is an experienced executive, management consultant and entrepreneur. Mr Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post-Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr Thakral ran the global life sciences business unit at Gerson Lehrman Group and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth.
    Mr Sujal Arun Shah Non-Executive Director Apr 2024
    Mr Shah brings two decades of experience as a biopharmaceutical executive and strategic advisor to the Opthea Board. Most recently, Mr Shah served as President and Chief Executive Officer at CymaBay Therapeutics, a clinicalstage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Mr Shah joined CymaBay as Chief Financial Officer, taking the company public in 2013. Prior to CymaBay, Mr Shah was a healthcare investment bankerfor Citigroup Inc. as well as Credit Suisse, where he wasresponsible for managing client relationships and executing strategic and financing related transactions for clients on life sciences. Mr Shah currently serves as Chairman of the Board of Tvardi Therapeutics and as a Director on the Board of Stratus Therapeutics.
    Mrs Karen Adams Company SecretaryVice President of Finance Jun 2021
    -
    Dr Frederic Guerard Chief Executive Officer Oct 2023
    -
    Judith Robertson Chief Commercial Officer
    -
    Frederic Guerard Chief Executive Officer
    -
    Timothy Morris Chief Financial Officer
    -
    Joel Naor Chief Medical Officer
    -
    Karen Adams Company SecretaryVice President of Finance
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 113,819,968 24.36%
    Citicorp Nominees Pty Limited 61,449,070 13.15%
    Usb Nominees Pty Ltd 35,562,811 7.61%
    JP Morgan Nominees Australia Pty Limited 34,576,016 7.40%
    Merrill Lynch (Australia) Nominees Pty Limited 23,329,680 4.99%
    National Nominees Limited 22,739,390 4.87%
    Bnp Paribas Noms Pty Ltd <Drp 15,855,958 3.39%
    Jagen Pty Ltd 11,581,484 2.48%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 6,875,408 1.47%
    Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 5,762,622 1.23%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,519,023 1.18%
    Ms Margaret Lynette Harvey 5,268,323 1.13%
    Armada Trading Pty Limited 5,005,806 1.07%
    Safo Trading Pty Ltd 3,641,130 0.78%
    Gaja Holdings 3,207,576 0.69%
    Safo Investments Pty Ltd <Safo Investments A/C> 3,039,766 0.65%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 3,000,000 0.64%
    Bilgola Nominees Pty Limited 2,934,490 0.63%
    Suibian Trading Pty Ltd 2,933,644 0.63%
    Sandhurst Trustees Ltd <Jmfg Consol A/C> 2,561,995 0.55%

    Profile

    since

    Note